Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
07
2022
accepted:
09
05
2023
medline:
25
5
2023
pubmed:
23
5
2023
entrez:
23
5
2023
Statut:
epublish
Résumé
RTS,S/AS01 induced anti-circumsporozoite protein (CSP) IgG antibodies are associated with the vaccine efficacy. There is currently no international standardisation of the assays used in the measurement of anti-CSP IgG antibody concentrations for use in evaluations of the vaccine's immunogenicity and/or efficacy. Here, we compared the levels of RTS,S/AS01 induced anti-CSP IgG antibodies measured using three different enzyme-Linked ImmunoSorbent Assays (ELISA). 196 plasma samples were randomly selected from the 447 samples collected during the RTS,S/AS01 phase IIb trial in 2007 from Kenyan children aged between 5-17 months. The vaccine-induced anti-CSP IgG antibodies were then measured using two independently developed ELISA protocols ('Kilifi-RTS,S' and 'Oxford-R21') and compared to the results from the reference 'Ghent-RTS,S' protocol for the same participants. For each pair of protocols, a deming regression model was fitted. Linear equations were then derived to aid in conversions into equivalent ELISA units. The agreement was assessed using Bland and Altman method. The anti-CSP IgG antibodies measured from the three ELISA protocols were in agreement, and were positively and linearly correlated; 'Oxford' and 'Kilifi' r = 0.93 (95% CI 0.91-0.95), 'Oxford' and 'Ghent' r = 0.94 (95% CI: 0.92-0.96), and 'Kilifi' and 'Ghent' r = 0.97 (95% CI: 0.96-0.98), p<0.0001 for all correlations. With the linearity, agreement and correlations established between the assays, conversion equations can be applied to convert results into equivalent units, enabling comparisons of immunogenicities across different vaccines of the same CSP antigens. This study highlights the need for the international harmonisation of anti-CSP antibody measurements.
Sections du résumé
BACKGROUND
RTS,S/AS01 induced anti-circumsporozoite protein (CSP) IgG antibodies are associated with the vaccine efficacy. There is currently no international standardisation of the assays used in the measurement of anti-CSP IgG antibody concentrations for use in evaluations of the vaccine's immunogenicity and/or efficacy. Here, we compared the levels of RTS,S/AS01 induced anti-CSP IgG antibodies measured using three different enzyme-Linked ImmunoSorbent Assays (ELISA).
METHODS
196 plasma samples were randomly selected from the 447 samples collected during the RTS,S/AS01 phase IIb trial in 2007 from Kenyan children aged between 5-17 months. The vaccine-induced anti-CSP IgG antibodies were then measured using two independently developed ELISA protocols ('Kilifi-RTS,S' and 'Oxford-R21') and compared to the results from the reference 'Ghent-RTS,S' protocol for the same participants. For each pair of protocols, a deming regression model was fitted. Linear equations were then derived to aid in conversions into equivalent ELISA units. The agreement was assessed using Bland and Altman method.
FINDINGS
The anti-CSP IgG antibodies measured from the three ELISA protocols were in agreement, and were positively and linearly correlated; 'Oxford' and 'Kilifi' r = 0.93 (95% CI 0.91-0.95), 'Oxford' and 'Ghent' r = 0.94 (95% CI: 0.92-0.96), and 'Kilifi' and 'Ghent' r = 0.97 (95% CI: 0.96-0.98), p<0.0001 for all correlations.
CONCLUSIONS
With the linearity, agreement and correlations established between the assays, conversion equations can be applied to convert results into equivalent units, enabling comparisons of immunogenicities across different vaccines of the same CSP antigens. This study highlights the need for the international harmonisation of anti-CSP antibody measurements.
Identifiants
pubmed: 37220123
doi: 10.1371/journal.pone.0286117
pii: PONE-D-22-21096
pmc: PMC10204981
doi:
Substances chimiques
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0286117Informations de copyright
Copyright: © 2023 Mugo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Lancet. 2021 May 15;397(10287):1809-1818
pubmed: 33964223
Lancet Infect Dis. 2015 Dec;15(12):1450-8
pubmed: 26342424
J Infect Dis. 1995 Jun;171(6):1576-85
pubmed: 7769295
Surv Immunol Res. 1982;1(4):371-4
pubmed: 6764850
BMC Med. 2014 Jul 10;12:117
pubmed: 25012228
J Infect Dis. 2009 Aug 1;200(3):337-46
pubmed: 19569965
N Engl J Med. 2008 Dec 11;359(24):2521-32
pubmed: 19064627
Malar J. 2021 Dec 2;20(1):452
pubmed: 34856981
PLoS Med. 2014 Jul 29;11(7):e1001685
pubmed: 25072396
N Engl J Med. 2021 Sep 9;385(11):1005-1017
pubmed: 34432975
Trials. 2007 Mar 26;8:11
pubmed: 17386091
PLoS One. 2013 Apr 16;8(4):e61395
pubmed: 23613845
Vaccine. 2013 Apr 18;31 Suppl 2:B233-43
pubmed: 23598488
Clin Chem. 1979 Mar;25(3):432-8
pubmed: 262186
N Engl J Med. 2016 Jun 30;374(26):2519-29
pubmed: 27355532
Sci Rep. 2017 Apr 19;7:46621
pubmed: 28422178
Front Immunol. 2018 Jul 25;9:1660
pubmed: 30090099
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
Malar J. 2009 Dec 30;8:312
pubmed: 20042088
N Engl J Med. 2013 Mar 21;368(12):1111-20
pubmed: 23514288